ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer
ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer
Recruiting · NCT05542407 · Registry updated 2026-01-29Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer | Body Weight, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasm Metastasis, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Connective and Soft Tissue, Neoplastic Processes, Nutritional and Metabolic Diseases, Overweight, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Urogenital Diseases, Urogenital Neoplasms, carcinosarcoma, disease, endometrial endometrioid adenocarcinoma, endometrium neoplasm, female reproductive system disorder, female reproductive system neoplasm, mixed neoplasm, neoplasm, nutritional disorder, obesity disorder, overnutrition, sarcoma, uterine disorder | Recruiting | Phase 1 | 2026-01-29 | NCT05542407 |
5 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Genentech, Inc. | 221 |
| Jazz Pharmaceuticals | 60 |
| National Cancer Institute (NCI) | 3015 |
| Oncoceutics, Inc. | 1 |
| UNC Lineberger Comprehensive Cancer Center | 125 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Lineberger Comprehensive Cancer Center | Chapel Hill | United States | 15 |